Biovista is a biotechnology company that profiles novel uses and side effects for existing drugs using their mechanism of action.
Biovista president Aris Persidis said they look forward to work with Novartis to enhance their drug discovery efforts.
"Our unique COSS technology offers significant advantages in terms of speed, comprehensiveness and depth of clinical outcome exploration, which we expect will help patients in need of novel solutions," Persidis said.